Literature DB >> 9049881

Mitoxantrone-induced DNA strand breaks in cell-cultures of malignant human astrocytoma and glioblastoma tumors.

M Senkal1, J C Tonn, R Schönmayr, W Schachenmayr, U Eickhoff, M Kemen, E Kollig.   

Abstract

In this study mitoxantrone (Mtx) induced DNA strand breaks were measured with the alkaline elution technique in short term cell cultures derived from human gliomas. Glioblastomas or astrocytomas from 5 patients who underwent intracranial surgery were cultured and incubated i h with different concentrations of Mtx (0, 0.01, 0.1 and 1.0 microgram/ml). The alkaline elution method was modified to measure DNA lesions in human gliomas. Mtx induced DNA strand breaks in a dose dependent manner in all cell cultures tested. There was a linear increase of DNA strand break frequency induced by Mtx between 0.01-1.0 microgram/ml. concerning these in vitro data, Mtx might be potentially useful for the treatment of patients with malignant brain tumors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9049881     DOI: 10.1023/a:1005792410604

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  19 in total

1.  Fractionation of DNA from mammalian cells by alkaline elution.

Authors:  K W Kohn; L C Erickson; R A Ewig; C A Friedman
Journal:  Biochemistry       Date:  1976-10-19       Impact factor: 3.162

2.  Improved microfluorometric DNA determination in biological material using 33258 Hoechst.

Authors:  C F Cesarone; C Bolognesi; L Santi
Journal:  Anal Biochem       Date:  1979-11-15       Impact factor: 3.365

Review 3.  Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity.

Authors:  H Lenk; U Müller; S Tanneberger
Journal:  Anticancer Res       Date:  1987 Nov-Dec       Impact factor: 2.480

Review 4.  Mitoxantrone: a novel anthracycline derivative.

Authors:  J Koeller; M Eble
Journal:  Clin Pharm       Date:  1988-08

5.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part II: Evaluation of patient- and drug-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; W Schachenmayr; R Schönmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

6.  The MTT assay for chemosensitivity testing of human tumors of the central nervous system. Part I: Evaluation of test-specific variables.

Authors:  G Nikkhah; J C Tonn; O Hoffmann; H P Kraemer; J L Darling; R Schönmayr; W Schachenmayr
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

7.  Long-term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators mAMSA and mitoxantrone.

Authors:  M E Fox; P J Smith
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

8.  Pharmacology of mitoxantrone: mode of action and pharmacokinetics.

Authors:  D S Alberts; Y M Peng; G T Bowden; W S Dalton; C Mackel
Journal:  Invest New Drugs       Date:  1985       Impact factor: 3.850

9.  Human central nervous system and plasma pharmacology of mitoxantrone.

Authors:  R M Green; D J Stewart; H Hugenholtz; M T Richard; M Thibault; V Montpetit
Journal:  J Neurooncol       Date:  1988       Impact factor: 4.130

10.  New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.

Authors:  S E Salmon; F L Meyskens; D S Alberts; B Soehnlen; L Young
Journal:  Cancer Treat Rep       Date:  1981 Jan-Feb
View more
  5 in total

1.  Systemic temozolomide combined with loco-regional mitoxantrone in treating recurrent glioblastoma.

Authors:  A Boiardi; M Eoli; A Salmaggi; E Lamperti; A Botturi; G Broggi; L Bissola; G Finocchiaro; A Silvani
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

2.  Intratumoral delivery of mitoxantrone in association with 90-Y radioimmunotherapy (RIT) in recurrent glioblastoma.

Authors:  Amerigo Boiardi; Mirco Bartolomei; Antonio Silvani; Marica Eoli; Andrea Salmaggi; Elena Lamperti; Ida Milanesi; Andrea Botturi; Paola Rocca; Lisa Bodei; Giovanni Broggi; Giovanni Paganelli
Journal:  J Neurooncol       Date:  2005-04       Impact factor: 4.130

3.  Efficacy of intratumoral delivery of mitoxantrone in recurrent malignant glial tumours.

Authors:  A Boiardi; M Eoli; A Salmaggi; B Zappacosta; L Fariselli; I Milanesi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  2001-08       Impact factor: 4.130

4.  Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.

Authors:  Marco Saini; Florian Roser; Samii Hussein; Madjid Samii; Mattia Bellinzona
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

5.  Treatment of recurrent glioblastoma: can local delivery of mitoxantrone improve survival?

Authors:  Amerigo Boiardi; Antonio Silvani; Marica Eoli; Elena Lamperti; Andrea Salmaggi; Paola Gaviani; Anna Fiumani; Andrea Botturi; Chiara Falcone; Alessandra Solari; Graziella Filippini; Francesco Di Meco; Giovanni Broggi
Journal:  J Neurooncol       Date:  2008-02-19       Impact factor: 4.130

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.